157 related articles for article (PubMed ID: 15061206)
41. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
[TBL] [Abstract][Full Text] [Related]
42. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
[TBL] [Abstract][Full Text] [Related]
43. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
44. The role of immunomodulatory drugs in multiple myeloma.
Anderson KC
Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
46. The treatment of relapsed and refractory multiple myeloma.
Richardson P; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Chauhan D; Munshi N; Anderson K
Hematology Am Soc Hematol Educ Program; 2007; ():317-23. PubMed ID: 18024646
[TBL] [Abstract][Full Text] [Related]
47. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
48. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
[TBL] [Abstract][Full Text] [Related]
49. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
[TBL] [Abstract][Full Text] [Related]
51. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
52. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
[TBL] [Abstract][Full Text] [Related]
53. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
54. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
Matsue K; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuchi M
Ann Hematol; 2010 Mar; 89(3):291-7. PubMed ID: 19693498
[TBL] [Abstract][Full Text] [Related]
55. Pomalidomide-based therapy for extramedullary multiple myeloma.
Li Y; Ji J; Lu H; Li J; Qu X
Hematology; 2022 Dec; 27(1):88-94. PubMed ID: 35068387
[TBL] [Abstract][Full Text] [Related]
56. [Effectivity of thalidomide and dexamethasone for the treatment of refractory multiple myeloma: a retrospective study of 36 consecutive cases].
Khosravi Shahi P; Díaz Muñoz de la Espada VM; Sabin Domínguez P; Encinas García S; Arranz Arija JA; Carrión Galindo JR; Pérez Manga G
Med Clin (Barc); 2007 Feb; 128(4):121-4. PubMed ID: 17288931
[TBL] [Abstract][Full Text] [Related]
57. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
59. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
[TBL] [Abstract][Full Text] [Related]
60. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Terpos E; Christoulas D; Kastritis E; Katodritou E; Papatheodorou A; Pouli A; Kyrtsonis MC; Michalis E; Papanikolaou X; Gkotzamanidou M; Koulieris E; Gavriatopoulou M; Zervas K; Dimopoulos MA;
Am J Hematol; 2014 Jan; 89(1):34-40. PubMed ID: 23983166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
